Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Intrinsic Bioprobes wins $1.27 million contract with NCI
June 2009
SHARING OPTIONS:

TEMPE, Ariz.Intrinsic Bioprobes Inc. announced in May the start of a contract with the National Cancer Institute (NCI) to develop multiplex mass spectrometric immunoassays for the detection of low-abundance, cancer-related proteins and peptides from bodily fluids. The contract is part of the NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research.

"The application of proteomics tools in the clinical setting lags far behind their use in basic science and drug discovery," says Dr. Dobrin Nedelkov, Intrinsic's scientific director. "The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.